Skip to main content
Top
Published in: Clinical Rheumatology 3/2006

01-05-2006 | Original Article

Lipid peroxidation and trace elements in systemic sclerosis

Authors: Mohammed Tikly, Kalavati Channa, Penny Theodorou, Mairam Gulumian

Published in: Clinical Rheumatology | Issue 3/2006

Login to get access

Abstract

Oxidative stress appears to be important in the causation and perpetuation of tissue injury and fibrosis in systemic sclerosis or scleroderma (SSc). We conducted a case-control study to assess lipid peroxidation levels as determined by measuring fasting plasma malondialdehyde (MDA) and serum levels of the trace elements selenium, iron, zinc and copper in SSc. Plasma MDA levels were almost tenfold higher in patients than in controls (p=0.00007), and an inverse relationship between MDA levels and disease duration (r=–0.52, p=0.044) was observed. Selenium levels were lower in patients than in controls (p=0.012). Within the patient cohort, copper correlated inversely with the total skin score (r=–0.52, p=0.03). Our findings provide further evidence that lipid peroxidation is increased and antioxidant capacity is reduced in SSc. The gradual decline in MDA levels with time suggests that antioxidant therapy, if to be useful in SSc, is most likely to be effective early in the course of the disease.
Literature
1.
go back to reference Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MIV (1994) Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483PubMed Herrick AL, Rieley F, Schofield D, Hollis S, Braganza JM, Jayson MIV (1994) Micronutrient antioxidant status in patients with primary Raynaud's phenomenon and systemic sclerosis. J Rheumatol 21:1477–1483PubMed
2.
go back to reference Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196:85–91CrossRefPubMed Simonini G, Cerinic MM, Generini S, Zoppi M, Anichini M, Cesaretti C et al (1999) Oxidative stress in systemic sclerosis. Mol Cell Biochem 196:85–91CrossRefPubMed
3.
go back to reference Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39:1146–1150PubMedCrossRef Stein CM, Tanner SB, Awad JA, Roberts LJ 2nd, Morrow JD (1996) Evidence of free radical-mediated injury (isoprostane overproduction) in scleroderma. Arthritis Rheum 39:1146–1150PubMedCrossRef
4.
5.
go back to reference Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJF (1992) Further evidence of increased polymorphonuclear activity in patients with Raynaud's phenomenon. Br J Rheumatol 31:375–380PubMedCrossRef Lau CS, Bridges AB, Muir A, Scott N, Bancroft A, Belch JJF (1992) Further evidence of increased polymorphonuclear activity in patients with Raynaud's phenomenon. Br J Rheumatol 31:375–380PubMedCrossRef
6.
go back to reference Tew MB, Reveille JD, Arnett FC, Friedman AW, McNearney T, Fischbach M et al (2001) Glutathione S-transferase genotypes in systemic sclerosis and their association with clinical manifestations in early disease. Genes Immun 2:236–238CrossRefPubMed Tew MB, Reveille JD, Arnett FC, Friedman AW, McNearney T, Fischbach M et al (2001) Glutathione S-transferase genotypes in systemic sclerosis and their association with clinical manifestations in early disease. Genes Immun 2:236–238CrossRefPubMed
7.
go back to reference Palmer CN, Young V, Ho M, Doney A, Belch JJ (2003) Association of common variation in glutathione S-transferase genes with premature development of cardiovascular disease in patients with systemic sclerosis. Arthritis Rheum 48:854–855PubMedCrossRef Palmer CN, Young V, Ho M, Doney A, Belch JJ (2003) Association of common variation in glutathione S-transferase genes with premature development of cardiovascular disease in patients with systemic sclerosis. Arthritis Rheum 48:854–855PubMedCrossRef
8.
go back to reference Tikly M, Marshall SE, Haldar NA, Gulumian M, Wordsworth P, Welsh KI (2004) Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis. Free Radic Biol Med 36:1403–1407CrossRefPubMed Tikly M, Marshall SE, Haldar NA, Gulumian M, Wordsworth P, Welsh KI (2004) Oxygen free radical scavenger enzyme polymorphisms in systemic sclerosis. Free Radic Biol Med 36:1403–1407CrossRefPubMed
9.
go back to reference Lundberg A-C,Åkesson A, Åkesson B (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51:1143–1148PubMed Lundberg A-C,Åkesson A, Åkesson B (1992) Dietary intake and nutritional status in patients with systemic sclerosis. Ann Rheum Dis 51:1143–1148PubMed
10.
go back to reference Herrick AL, Worthington H, Rieley F, Clarke D, Schofield D, Braganza JM et al (1996) Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol 23:650–653PubMed Herrick AL, Worthington H, Rieley F, Clarke D, Schofield D, Braganza JM et al (1996) Dietary intake of micronutrient antioxidants in relation to blood levels in patients with systemic sclerosis. J Rheumatol 23:650–653PubMed
11.
go back to reference Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78–85PubMedCrossRef Murrell DF (1993) A radical proposal for the pathogenesis of scleroderma. J Am Acad Dermatol 28:78–85PubMedCrossRef
12.
go back to reference Del Maestro RF, Thaw HH, Bjork J, Planker M, Arfors KE (1980) Free radicals as mediators of tissue injury. Acta Physiol Scand 492:43–57 Del Maestro RF, Thaw HH, Bjork J, Planker M, Arfors KE (1980) Free radicals as mediators of tissue injury. Acta Physiol Scand 492:43–57
13.
go back to reference Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 43:894 900CrossRefPubMed Solans R, Motta C, Sola R, La Ville AE, Lima J, Simeon P et al (2000) Abnormalities of erythrocyte membrane fluidity, lipid composition, and lipid peroxidation in systemic sclerosis: evidence of free radical-mediated injury. Arthritis Rheum 43:894 900CrossRefPubMed
14.
go back to reference Halliwell B, Gutteridge JMC (1999) Free radicals in biology and medicine. Oxford University Press, Oxford Halliwell B, Gutteridge JMC (1999) Free radicals in biology and medicine. Oxford University Press, Oxford
15.
go back to reference Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalysed oxidation reactions: implications for pathogenesis. J Exp Med 185:71–79CrossRefPubMed Casciola-Rosen L, Wigley F, Rosen A (1997) Scleroderma autoantigens are uniquely fragmented by metal-catalysed oxidation reactions: implications for pathogenesis. J Exp Med 185:71–79CrossRefPubMed
16.
17.
go back to reference Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee (1980) Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 23:581–590CrossRef
18.
go back to reference LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TAJ et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205PubMed LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TAJ et al (1988) Scleroderma (systemic sclerosis): classification, subsets, and pathogenesis. J Rheumatol 15:202–205PubMed
19.
go back to reference Tager RE, Tikly M (1999) Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology 38:397–400CrossRefPubMed Tager RE, Tikly M (1999) Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans. Rheumatology 38:397–400CrossRefPubMed
20.
go back to reference Clements PJ, Lachenbruch PA, Seibold JR, White B, Weiner S, Martin R et al (1995) Inter- and intra-observer variability of total skin thickness score (modified-Rodnan) in systemic sclerosis (SSc). J Rheumatol 22:1281–1285PubMed Clements PJ, Lachenbruch PA, Seibold JR, White B, Weiner S, Martin R et al (1995) Inter- and intra-observer variability of total skin thickness score (modified-Rodnan) in systemic sclerosis (SSc). J Rheumatol 22:1281–1285PubMed
21.
go back to reference Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145PubMedCrossRef Fries JF, Spitz P, Kraines RG, Holman HR (1980) Measurement of patient outcome in arthritis. Arthritis Rheum 23:137–145PubMedCrossRef
22.
go back to reference Wong JW, Ebeler SE, Rivkah-Isseroff R, Shibamoto T (1994) Analysis of malondialdehyde in biological samples by capillary gas chromatography. Anal Biochem 220:73–81CrossRefPubMed Wong JW, Ebeler SE, Rivkah-Isseroff R, Shibamoto T (1994) Analysis of malondialdehyde in biological samples by capillary gas chromatography. Anal Biochem 220:73–81CrossRefPubMed
23.
go back to reference Jiminez SA, Hitraya E, Varga J (1996) Pathogenesis of scleroderma. Rheum Dis Clin North Am 22:647–674CrossRefPubMed Jiminez SA, Hitraya E, Varga J (1996) Pathogenesis of scleroderma. Rheum Dis Clin North Am 22:647–674CrossRefPubMed
24.
go back to reference Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology 38:309–315CrossRefPubMed Denton CP, Bunce TD, Dorado MB, Roberts Z, Wilson H, Howell K et al (1999) Probucol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud's phenomenon. Rheumatology 38:309–315CrossRefPubMed
25.
go back to reference Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356PubMed Herrick AL, Hollis S, Schofield D, Rieley F, Blann A, Griffin K et al (2000) A double-blind placebo-controlled trial of antioxidant therapy in limited cutaneous systemic sclerosis. Clin Exp Rheumatol 18:349–356PubMed
26.
go back to reference Leonarduzzi G, Scavazza A, Biasa F, Chiarpotto E, Camandola S, Vogl S et al (1997) The lipid peroxidation endproduct 4-hydroxy-2,3-nonenal up-regulates transforming growth factor-b1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 11:851–857PubMed Leonarduzzi G, Scavazza A, Biasa F, Chiarpotto E, Camandola S, Vogl S et al (1997) The lipid peroxidation endproduct 4-hydroxy-2,3-nonenal up-regulates transforming growth factor-b1 expression in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 11:851–857PubMed
27.
go back to reference Gries CL, Scott ML (1972) Pathology of selenium deficiency in the chick. J Nutr 102:1287–1296PubMed Gries CL, Scott ML (1972) Pathology of selenium deficiency in the chick. J Nutr 102:1287–1296PubMed
Metadata
Title
Lipid peroxidation and trace elements in systemic sclerosis
Authors
Mohammed Tikly
Kalavati Channa
Penny Theodorou
Mairam Gulumian
Publication date
01-05-2006
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 3/2006
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-005-0013-4

Other articles of this Issue 3/2006

Clinical Rheumatology 3/2006 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine